SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Novartis pelacarsen misses Phase 3 primary endpoint versus placebo

Novartis said pelacarsen did not meet the primary endpoint in a Phase 3 study, failing to reduce the risk of cardiovascular events versus placebo, including deaths, heart attacks and strokes.

NOT

Novartis said its heart disease drug pelacarsen did not meet the primary endpoint in a Phase 3 study. The company said on Friday that pelacarsen did not reduce the risk of cardiovascular events, including deaths, heart attacks and strokes, versus placebo. The drug did succeed…

Related stories